



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Lawrence B. Bugaisky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Crystal D. Sayles
Edward W. Yee
Albert L. Ferro
Donald R. Banowitz
Peter A. Jackman
Molly A. McCall
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Albert J. Fasulo II
Eldora Ellison Floyd
W. Russell Swindell

Thomas C. Flala
Brian J. Del Buono
Virgil Lee Beaton
Reginald D. Lucas
Kimberly N. Reddick
Theodore A. Wood
Elizabeth J. Haanes
Bruce E. Chalker
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhulier
Rae Lynn Prengaman
Jane Shershenovich
Lawrence J. Carroll
George S. Bardmesser
Daniel A. Klien
Rodney G. Maze
Jason D. Eisenberg
Michael A. Specht

Registered Patent Agents*
Karen R. Markowicz
Andrea J. Kamage
Nancy J. Leith
Ann E. Summerfield
Helene C. Carlson
Gaby L. Longworth
Matthew J. Dowd
Aaron L. Schwartz
Angelique G. Uy
Boris A. Matvenko
Mary B. Tung
Katrina Y. Pei
Bryan L. Skelton
Robert A. Schwartzman
John J. Figueroa
Timothy A. Doyle
Jennifer R. Mahalingappa

Senior Counsel
Samuel L. Fox
Kenneth C. Bass III
Lisa A. Dunner

*Admitted only in Maryland
*Admitted only in Virginia
*Admitted only in Texas
•Practice Limited to
Federal Agencies

1634
Box 570

November 21, 2002

WRITER'S DIRECT NUMBER:
(202) 371-2560

INTERNET ADDRESS:
RESMOND@SKGF.COM

RECEIVED

NOV 26 2002

Art Unit 1634

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1800/2900

Re: U.S. Utility Patent Application
Appl. No. 09/515,513; Filed: February 29, 2000
For: **cDNA Synthesis Improvements**
Inventors: Li *et al.*
Our Ref: 0942.4870001/RWE/M-G

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Amendment and Submission of Substitute Sequence Listing Under 37 C.F.R. § 1.825(a);
2. 1 page of a paper copy of a Substitute Sequence Listing;
3. A computer readable copy of the Substitute Sequence Listing; and
4. One (1) return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
November 21, 2002
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond
Attorney for Applicants
Registration No. 32,893

Enclosures

SKGF_DC1:76898.1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LI *et al.*

Appl. No. 09/515,513

Filed: February 29, 2000

For: **cDNA Synthesis Improvements**

Confirmation No. 1139

Art Unit: 1634

Examiner: Taylor, J.

Atty. Docket: 0942.4870001/RWE/M-G

**Amendment and Submission of Substitute Sequence Listing
Under 37 C.F.R. § 1.825(a)**

RECEIVED

NOV 26 2002

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

In compliance with 37 C.F.R. § 1.825(a), Applicants submit substitute sheets to amend the paper copy of the Sequence Listing.

In the Specification:

Please cancel the existing Sequence Listing for the above-identified application, replace it with the substitute Sequence Listing appended hereto, and insert the same at the end of the application.

Please substitute the current version of the paragraph on page 31, lines 23-29, with the following paragraph:

62

The annealing mix was prepared by mixing 1 µg of MAP4 mRNA and biotinylated *Not I* oligo(dT)₂₅ primer ((Biotin)₄ GACTAGTTCTAGAT CGCGAGCGG CCGCCCTTTTT TTTTTTTTTTTT TTTTTTTT (SEQ ID NO:1); see WO 98/51699) in the desired molar ratio of oligo (dT)/mRNA of 0:1, 1:1 or 15:1 in thin-walled PCR tubes and bringing the volume up to 10 µl with water. If several tubes are identical, they may be made in one batch and aliquotted accordingly. The annealing mix was kept on ice.